Eris Lifesciences Ltd

Net profit of ERIS Lifesciences rose 200.10% to Rs 281.61 crore in the quarter ended March 2026 as against Rs 93.84 crore during the previous quarter ended March 2025. Sales rose 7.07% to Rs 752.29 crore in the quarter ended March 2026 as against Rs 702.60 crore during the previous quarter ended March 2025. For the full year,net profit rose 76.08% to Rs 619.52 crore in the year ended March 2026 as against Rs 351.84 crore during the previous year ended March 2025. Sales rose 8.18% to Rs 3114.89 crore in the year ended March 2026 as against Rs 2879.26 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales752.29702.60 7 3114.892879.26 8 OPM %36.2135.92 -35.9635.33 - PBDT228.98206.12 11 935.28804.33 16 PBT159.41128.87 24 655.78488.87 34 NP281.6193.84 200 619.52351.84 76 Powered by Capital Market - Live

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 20 May 2026, inter alia, have recommended the interim dividend of Rs 7.21 per equity Share (i.e. 721%) , subject to the approval of the shareholders.

Total revenue from operations rose 7.26% to Rs 756.56 crore in Q4 FY26 over Q4 FY25. Profit before tax (PBT) stood at Rs 159.41 crore in Q4 FY26, up 23.69% from Rs 128.87 crore recorded in the same quarter last year. During the quarter EBITDA stood at Rs 274 crore, up 8% compared with Rs 252 crore posted in same quarter last year. EBITDA margin expanded to 36.2% in Q4 FY26 as against 35.8% in Q4 FY25. Revenue from domestic branded formulation (DBF) business jumped 12% YoY to Rs 671 crore in Q4 FY26. The International Business fell 8% to Rs 86 crore in Q4 FY26. The company declared an interim dividend of Rs 7.21 per fully paid-up equity share of Re 1 each (721%) for FY27. It has fixed Friday, May 29, 2026, as the record date to determine shareholders' eligibility for the interim dividend. The dividend will be paid on or before June 19, 2026. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products. Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 20 May 2026.

ERIS Lifesciences has allotted 24,396 equity shares under ESOP on 11 May 2026. The paid-up share capital of the Company accordingly stands increased from Rs 13,85,42,887/- (13,85,42,887 equity shares of Re 1/- each) to Rs 13,85,67,256/- (13,85,67,256 equity shares of Re 1/- each).

Eris Lifesciences has received affirmation in credit ratings for non convertible debentures and bank facilities at IND AA; Stable/ IND A1+ from India Ratings and Research. The company's issuer rating has been affirmed at IND AA; Stable.

HALMED (Agency for Medicinal Products and Medical Devices of Croatia) inspected the unit-1 (general liquid and dry powder injectables) and Unit-2 (betalactam dry powder injectables) from 9 to 13th March 2026. Following the inspection, the company received a list of non-compliance observations for Unit-1 and Unit-2. According to the company, the observations are procedural in nature and require improvement to achieve compliance with the principles and guidelines of good manufacturing practice (GMP) under the Directive (EU) 2017/1572. The company said it will undertake remediation measures, submit corrective and preventive action plans (CAPAs), and request HALMED to conduct a follow-up inspection. The company said the impact on current business operations is likely to be minimal while commercialization of the EU-CDMO product pipeline may face delays. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products. The company has reported 19.05% increase in consolidated net profit to Rs 99.72 crore on a 10.91% increase in revenue to Rs 800.89 crore in Q3 FY26 as compared with Q3 FY25.

ERIS Lifesciences has appointed Vineet Varma (DIN: 11600100) as an Additional Director (Non-executive, Independent) of the Company for a term of five years, effective from 14 March 2026, subject to the approval of the members.Powered by Capital Market - Live

ERIS Lifesciences has allotted 19,624 equity shares under ESOP on 12 March 2026. With this allotment, the paid up equity share capital stands increased to Rs. 13,85,42,887/- (13,85,42,887 equity shares of Re. 1/- each).Powered by Capital Market - Live

Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy in the management of Type 2 diabetes and chronic weight management driven by robust clinical outcomes in glycemic control and weight reduction. With India witnessing a rapidly growing diabetic population and increasing awareness around obesity management, GLP-1 therapies represent a high-growth opportunity within the metabolic segment. Eris has built a strong and scalable presence in diabetology over the years, supported by a wide specialist reach and deep engagement with endocrinologists, diabetologists and physicians across India. The addition of semaglutide is expected to further strengthen Eris' portfolio in advanced diabetes therapies and enhance its participation in next-generation metabolic treatments. Natco Pharma has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide for the Indian market, paving the way for a launch expected in March 2026. The product will target Type 2 diabetes management aligning with unmet needs in India's expanding metabolic care landscape. This collaboration builds on both companies' complementary strengths: Eris's robust commercial and diabetes franchise presence, and Natco's manufacturing and regulatory prowess in complex formulations. Amit Bakshi, chairman & managing director, Eris Lifesciences, said: Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. He further added that Eris has been proactively preparing its commercial strategy to participate meaningfully in the GLP-1 opportunity and views this partnership as a long-term value driver for the company. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products. The company has reported 19.05% increase in consolidated net profit to Rs 99.72 crore on a 10.91% increase in revenue to Rs 800.89 crore in Q3 FY26 as compared with Q3 FY25. Powered by Capital Market - Live